Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Hold” from Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.80.

A number of equities research analysts recently issued reports on XERS shares. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th.

Xeris Biopharma Trading Down 2.0%

Xeris Biopharma stock opened at $6.79 on Friday. The stock has a market cap of $1.17 billion, a P/E ratio of 113.17 and a beta of 0.78. Xeris Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The firm’s fifty day moving average price is $6.19 and its 200-day moving average price is $6.58. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Equities research analysts forecast that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the transaction, the director owned 126,500 shares of the company’s stock, valued at $770,385. This represents a 11.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Marla Persky sold 15,500 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total transaction of $91,450.00. Following the completion of the transaction, the director directly owned 126,500 shares in the company, valued at $746,350. The trade was a 10.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,335 shares of company stock valued at $766,733 in the last ninety days. 4.35% of the stock is owned by insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors have recently made changes to their positions in XERS. UBS Group AG increased its holdings in shares of Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after buying an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after buying an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after buying an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC increased its holdings in shares of Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after buying an additional 873,236 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.